Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Examining Opioid-Related Hospitalizations for Patients With Cancer

April 2, 2019
By Leah Lawrence
Article

Researchers looked at the trends and risk factors for opioid-related hospitalizations among patients with cancer.

Patients with cancer were rarely hospitalized for opioid-related reasons, according to a study published recently in JAMA Oncology. Although rates are increasing at a low rate over time, most of the hospitalizations are associated with non-heroin opioid poisoning, the study showed.

“In light of the wider opioid epidemic, oncologists and palliative care clinicians frequently balance providing patients with legitimate access to opioids while protecting them and the general public from the risks associated with prescribing these medications,” wrote Isaac S. Chua, MD, of Dana-Farber Cancer Institute, and colleagues in a research letter.

Chua and colleagues looked at the trends and risk factors for opioid-related hospitalizations among patients with cancer between 2006 and 2014 using data from the US National Inpatient Sample (NIS) of the Healthcare Cost and Utilization Project (HCUP). The primary outcome was opioid-related hospitalizations among adults age 18 or older.

Of the more than 25 million hospitalizations for patients with cancer, only 0.06% were related to opioids. From 2006 to 2014, the average number of opioid-related hospitalizations increased to 78.9 admissions per year (P = .01).

The majority of hospitalizations were non-heroin related (88.0%). The researchers identified several factors associated with opioid-related hospitalizations for patients with cancer, such as drug abuse (odds ratio [OR], 7.92; 95% CI, 6.95–9.02), depression (OR, 2.34; 95% CI, 2.13–2.58), psychotic disorder (OR, 4.13; 95% CI, 3.66–4.65), white race, younger age, and year of hospitalization.

“Prior to prescribing opioids for cancer-related pain, routinely screening patients using standardized tools based on these associated factors (eg, Opioid Risk Tool) may identify those patients with the greatest risk of an opioid-related hospitalization,” the researchers wrote. “Additional research on opioid risk screening and management for patients with combined cancer and substance use disorders is needed.”

Jon Mark Hirshon, MD, PhD, MPH, professor in the department of emergency medicine at the University of Maryland School of Science, told Cancer Network that these types of studies are important because “the issue of opioid misuse and abuse remains a significant and troubling societal problem causing widespread morbidity and mortality.”

“As a practicing emergency physician in inner-city Baltimore, I see this problem multiple times every shift. However, as noted within the article, the impact of this problem among patients with cancer is quite rare (0.06% of admissions) and has a very low rate of increase,” Hirshon said. “There are some weaknesses to the research, as it may underestimate the rate of the problem because it is based solely upon the primary diagnosis field and may have missed the diagnosis if placed in a secondary field. However, in the end, the article does not significantly impact clinical practice of emergency medicine and the need to remain vigilant both to the pain treatment needs of patients with cancer, as well as the continuing scourge of opioid misuse and abuse regardless of the patient population.”

Recent Videos
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
Related Content
Advertisement

The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.

IDMC Recommends Continuation of ELI-002 7P Trial in PDAC

Roman Fabbricatore
August 5th 2025
Article

The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.


Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.


At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.

TIL Therapy Provides Excitement Despite Room to Grow in Melanoma Care

Tim Cortese
August 5th 2025
Article

At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.


Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
July 31st 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.


More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Russ Conroy
August 4th 2025
Article

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.


Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Roman Fabbricatore
August 4th 2025
Article

Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.

Related Content
Advertisement

The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.

IDMC Recommends Continuation of ELI-002 7P Trial in PDAC

Roman Fabbricatore
August 5th 2025
Article

The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.


Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.


At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.

TIL Therapy Provides Excitement Despite Room to Grow in Melanoma Care

Tim Cortese
August 5th 2025
Article

At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.


Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
July 31st 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.


More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Russ Conroy
August 4th 2025
Article

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.


Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Roman Fabbricatore
August 4th 2025
Article

Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.